Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT01470131
Title A Phase 3 Study to Evaluate Efficacy and Safety of Masitinib in Patients With Relapse or Refractory Multiple Myeloma
Recruitment Terminated
Gender both
Phase Phase III
Variant Requirements No
Sponsors AB Science
Indications

multiple myeloma

Therapies

Masitinib

Bortezomib + Dexamethasone

Age Groups: adult
Covered Countries USA | FRA


No variant requirements are available.